NASDAQ : VOR
Vor Biopharma Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 19.53 USD (Oct 30, 2026, 2:45 PM EDT) · Market cap 1.16B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.21B |
| Enterprise Value | 730.28M |
Dates
| Measure | Value |
|---|
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.43M |
| Shares Outstanding | 61.43M |
| Shares Change (YoY) | +682.04% |
| Shares Change (QoQ) | +9.88% |
| Owned by Insiders (%) | 1.93% |
| Owned by Institutions (%) | 65.95% |
| Float | 42.54M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 0.64 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 0.54 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 13.50 |
| Quick Ratio | 13.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -27.45% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -32.11% |
| Weighted Average Cost of Capital (WACC) | 14.02% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $17.81M |
| Employee Count | 76 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.78 |
| 52-Week Price Change | -22.82% |
| 50-Day Moving Average | 20.75 |
| 200-Day Moving Average | 17.34 |
| Relative Strength Index (RSI) | 50.61 |
| Average Volume (20 Days) | 806,762 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.45M |
| Short Previous Month | 7.81M |
| Short % of Shares Out | 12.12% |
| Short % of Float | 17.50% |
| Short Ratio (days to cover) | 5.69 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -147.71M |
| Pretax Income | 1.35B |
| Net Income | 1.35B |
| EBITDA | -147.58M |
| EBIT | -147.71M |
| Earnings Per Share (EPS) | $30.51 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 481.55M |
| Total Debt | 2.81M |
| Net Cash | 478.74M |
| Net Cash Per Share | $7.79 |
| Equity (Book Value) | -137.17M |
| Book Value Per Share | -2.23 |
| Working Capital | 454.18M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -119.17M |
| Capital Expenditures | -507,000 |
| Depreciation & Amortization | 126,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -119.68M |
| FCF Per Share | -$1.95 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -682.04% |
| Shareholder Yield | -682.04% |
| Earnings Yield | 155.04% |
| FCF Yield | -9.90% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $39.00 |
| Price Target Difference | 98.17% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Sep 19, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |